A private equity consortium has become the latest bidder to bow to pressure from investors and sweeten its offer for artificial joint maker Biomet by nearly 5%.
Biomet recommended shareholders support the $11.4bn (€8.5bn) bid from private equity groups Blackstone Group, Goldman Sachs Capital Partners, Kohlberg Kravis Roberts and TPG.